Case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma
A patient with refractory PBL achieved durable complete remission after CD19 and CD22 CAR-T therapies, suggesting this treatment may be effective for patients with refractory or relapsing PBL.
Authors
- Zengjun Li (ORCID: https://orcid.org/0000-0003-0787-8089)
- Lijie Xing (ORCID: https://orcid.org/0000-0001-9737-0021)
- Ke Lu
- Haichen Wei
- Ping Li (ORCID: https://orcid.org/0000-0002-4926-3835)
- Wenjun Zhang (ORCID: https://orcid.org/0000-0001-8264-0754)
- Hui Wang (ORCID: https://orcid.org/0000-0003-0431-4931)
- Yanran Hu (ORCID: https://orcid.org/0000-0002-5188-1851)
- Dan Liu (ORCID: https://orcid.org/0009-0004-5649-3948)
Institutions
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1697566
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Shandong Province
- Chinese Society of Clinical Oncology